

IDEC Pharmaceuticals Corporation

**Briefing Document of ⁹⁰Yttrium Ibritumomab Tiuxetan
Radioimmunotherapy Regimen**

Erratum to page 74 (Table 48) and page 75 (Figure 17)

The sacral image-derived red marrow dosimetry results for 15 patients presented in Table 48 and Figure 17 are incorrect. The correct values are: ¹¹¹In ibritumomab tiuxetan dose factor 0.7 cGy/mCi (range: 0.4 - 0.8 cGy/mCi), ⁹⁰Y ibritumomab tiuxetan dose factor 4.7 cGy/mCi (range: 2.6 - 6.8 cGy/mCi), ⁹⁰Y ibritumomab tiuxetan radiation absorbed dose 143 cGy (range: 81-190 cGy).